1. OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas. (19th September 2018) Authors: Platten, M; Schilling, D; Bunse, L; Wick, A; Bunse, T; Riehl, D; Green, E; Sanghvi, K; Karapanagiotou-Schenkel, I; Harting, I; Sahm, F; Steinbach, J; Weyerbrock, A; Hense, J; Misch, M; Krex, D; Setvanovic, S; Tabatabai, G; von Deimling, A; Schmitt, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas. (19th September 2018) Authors: Platten, M; Schilling, D; Bunse, L; Wick, A; Bunse, T; Riehl, D; Green, E; Sanghvi, K; Karapanagiotou-Schenkel, I; Harting, I; Sahm, F; Steinbach, J; Weyerbrock, A; Hense, J; Misch, M; Krex, D; Setvanovic, S; Tabatabai, G; von Deimling, A; Schmitt, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗